Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients.
Philip Bonomi , Mary Jo Fidler , Palmi Shah , Jeffrey Borgia
Cancers 11 ( 11) 1619
2
2019
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
Benjamin T. Gielda , James C. Marsh , Thomas W. Zusag , L. Penfield Faber
Journal of Thoracic Oncology 6 ( 6) 1079 -1086
13
2011
Patterns-of-failure after helical tomotherapy-based chemoradiotherapy for head and neck cancer: implications for CTV margin, elective nodal dose and bilateral parotid sparing.
Virag Dandekar , Tiffany Morgan , Julius Turian , Mary Jo Fidler
Oral Oncology 50 ( 5) 520 -526
21
2014
Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis
David J. Sher , David L. Schwartz , Lucien Nedzi , Saad Khan
Oral Oncology 54 58 -67
15
2016
Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer
John Langenfeld , Jason M. Schenkel , Mary Jo Fidler , Emily S. Ruiz
Proceedings of the National Academy of Sciences of the United States of America 117 ( 2) 1119 -1128
108
2020
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients
Mary Jo Fidler , Cristina L. Fhied , Joanna Roder , Sanjib Basu
BMC Cancer 18 ( 1) 310
18
2018
Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale.
Sean O’Mahony , Susan Nathan , Roozbeh Mohajer , Philip Bonomi
American Journal of Hospice and Palliative Medicine 33 ( 4) 374 -380
9
2016
Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
Benjamin T. Gielda , Par Mehta , Atif Khan , James C. Marsh
International Journal of Radiation Oncology Biology Physics 81 ( 4) 985 -991
12
2011
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC
Fabrice Barlesi , Edward B. Garon , Dong-Wan Kim , Enriqueta Felip
Journal of Thoracic Oncology 14 ( 5) 793 -801
17
2019
Heterogeneity in the clinical presentation, diagnosis, and treatment initiation of p16-positive oropharyngeal cancer.
Anish Raman , Neilayan Sen , Ethan Ritz , Mary Jo Fidler
American Journal of Otolaryngology 40 ( 5) 626 -630
3
2019
Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0–2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response
Ellis Ziel , Gregory Hermann , Neilayan Sen , Philip Bonomi
Journal of Thoracic Oncology 10 ( 10) 1475 -1480
7
2015
Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls:
Mary Jo Fidler , David D. Shersher , Jeffrey A. Borgia , Philip Bonomi
Therapeutic Advances in Medical Oncology 4 ( 2) 51 -60
56
2012
Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung
Neeta Somaiah , Mary Jo Fidler , Elizabeth Garrett-Mayer , Amy Wahlquist
Oncoscience 1 ( 8) 522 -528
15
2014
Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer.
David J. Sher , Mary Jo Fidler , Michael J. Liptay , Matthew Koshy
Lung Cancer 88 ( 3) 267 -274
21
2015
Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients
Philip Bonomi , Marta Batus , Mary Jo Fidler , Jeffrey A. Borgia
Annals of Translational Medicine 5 ( 6) 152 -152
3
2017
Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.
David J. Sher , Benjamin T. Gielda , Michael J. Liptay , William H. Warren
Clinical Lung Cancer 14 ( 4) 370 -375
6
2013
PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment
Roy S. Herbst , Paul Baas , Jose L. Perez-Gracia , Enriqueta Felip
Journal of Thoracic Oncology 11 ( 10)
3
2016
Prevalence and Predictors of Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer in the National Cancer Database: Importance of Socioeconomic Status and Treating Institution
David J. Sher , Michael J. Liptay , Mary Jo Fidler
International Journal of Radiation Oncology Biology Physics 89 ( 2) 303 -312
16
2014
Thinking Outside the Abdomen: A Rare Case of Pancreatic Metastases: 1226
Natasha Shah , Rama Behara , Mary Jo Fidler , Shriram Jakate
The American Journal of Gastroenterology 111
2016
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
Shirish M. Gadgeel , Nathan A. Pennell , Mary Jo Fidler , Balazs Halmos
Journal of Thoracic Oncology 13 ( 9) 1393 -1399
92
2018